当前位置:
X-MOL 学术
›
Trends Pharmacol. Sci.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Targeting Mutant KRAS for Immunogenic Cell Death Induction.
Trends in Pharmacological Sciences ( IF 13.8 ) Pub Date : 2019-12-06 , DOI: 10.1016/j.tips.2019.11.004 Lorenzo Galluzzi 1
Trends in Pharmacological Sciences ( IF 13.8 ) Pub Date : 2019-12-06 , DOI: 10.1016/j.tips.2019.11.004 Lorenzo Galluzzi 1
Affiliation
Although somatic KRAS mutations are common in human tumors, no inhibitor of mutant KRAS was clinically available until recently. Canon and colleagues describe the ability of a clinically available KRASG12C inhibitor to drive immunogenic cancer cell death, thus constituting a promising combinatorial partner for immune checkpoint blockers.
中文翻译:
靶向突变KRAS进行免疫原性细胞死亡诱导。
尽管体KRAS突变在人类肿瘤中很常见,但直到最近临床上还没有突变KRAS抑制剂的临床应用。佳能及其同事描述了临床上可用的KRASG12C抑制剂驱动免疫原性癌细胞死亡的能力,从而构成了免疫检查点阻滞剂的有希望的组合伙伴。
更新日期:2019-12-07
中文翻译:
靶向突变KRAS进行免疫原性细胞死亡诱导。
尽管体KRAS突变在人类肿瘤中很常见,但直到最近临床上还没有突变KRAS抑制剂的临床应用。佳能及其同事描述了临床上可用的KRASG12C抑制剂驱动免疫原性癌细胞死亡的能力,从而构成了免疫检查点阻滞剂的有希望的组合伙伴。